Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared a post on X about a paper by M. Schmidt et al. published in ESMO Open:
“A common worldwide practice is to give chemo prior to ET to patients with untreated HR+ MBC. Multiple randomized studies have now proved that this strategy is inferior.
Glad to see the PADMA study published in ESMO Open, showing dramatically longer PFS with ET/palbo vs chemo.”
Title: First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
Authors: M. Schmidt, M. Thill, J. Rey, B. Rautenberg, V. Bjelic-Radisic, T. Decker, J. Rom, M. Kögel, K. Lübbe, A. Nacke, S. Seiler, M. Just, V. Müller, R. Buss-Steidle, J. Terhaag, C. Mundhenke, C. Denkert, J. Holtschmidt, S. Loibl
Read the Full Article.
SACI-IO HR+ Trial: 5 Promising Findings in Metastatic Breast Cancer
